- Created: Thursday, 08 October 2015 15:05
Annapolis, Md.— On October 8, the Honorable Doris O. Matsui (D-CA) entered into the Congressional Record her statement recognizing the third annual International Plasma Awareness Week (IPAW), to be celebrated October 11-17.
IPAW is sponsored by the Plasma Protein Therapeutics Association (PPTA) and its member companies, and is designed to:
- Raise global awareness about plasma donation
- Recognize the contributions of plasma donors in saving and improving lives
- Increase understanding about lifesaving plasma protein therapies and rare diseases
Plasma protein therapies, which include plasma-derived therapies and recombinant analogs, are used to treat chronic, life-threatening diseases including bleeding disorders, primary immune deficiencies, alpha-1 antitrypsin deficiency and certain rare neurological disorders. In addition, these therapies are used in emergency and surgical medicine.
PPTA applauds Congresswoman Matsui for her continued support of the plasma protein therapeutics industry and its patients. She is a longtime champion of rare diseases and access to care issues, with an important focus on Primary Immunodeficiency Diseases (PIDD) patients. Rep. Matsui co-authored and advocated for the passage of the Medicare IVIG Access Act, which allows PIDD patients to receive life-saving therapies in their homes.
"The Source plasma industry appreciates Congresswoman Matsui's continued support of patient access to plasma protein therapies. Her recognition of the lifesaving role of source plasma donors to help patients live productive lives is exemplified in today's Statement."said Joshua Penrod, PPTA Vice President, Source and International Affairs.
Congresswoman Matsui’s statement in recognition of IPAW is important in creating awareness of the life-saving gift of plasma protein therapies. A copy of the statement can be found on the PPTA website. If you have any questions, please contact Julie Birkofer, Senior Vice President North America & Global Health Policy, at the Association.
The Plasma Protein Therapeutics Association (PPTA), a global industry trade association, represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. Millions of people use these therapies worldwide to treat a variety of diseases and serious medical conditions. PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors and patients.
Media and Information
The Hilfenhaus Award conferred to Prof. Farkas at the IPPC 2017 +
The 2017 Hilfenhaus Award was bestowed to Professor Henriette Farkas, MD, Ph.D., DSc, during IPPC 2017 for her work related to treating those suffering from Hereditary Angioedema (HAE) and working to improve treatments and patients’ quality of life. She is professor of allergology and clinical immunology at the Hungarian Angioedema Center at Semmelweis University in Budapest, Hungary.Read More
Highlights from IPPC 2017 +
Mr. Bruno Santoni, Executive Director, PPTA Europe, opened the well-attended IPPC 2017 welcoming the more than 300 attendees to Prague. PPTA thanks its sponsors who help make the IPPC possible. Download the IPPC app for a complete list of sessions and many of the presentations.Read More
PPTA Remembers John W. Walsh +